Herbal granules aim to slow Alzheimer's in major trial
NCT ID NCT06534723
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether Wujia Yizhi granules, a traditional herbal medicine, can safely slow cognitive decline in people with mild-to-moderate Alzheimer's dementia. About 570 participants aged 50-80 will receive either the granules or a placebo for 12 months. Researchers will measure changes in memory and daily function using standard Alzheimer's tests.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Wujia Yizhi granules (herbal medicine)
- What this could lead to
- If successful, this could provide a new herbal treatment option to slow cognitive decline in mild-to-moderate Alzheimer's patients.
- What could go wrong
- This is an early-phase 3 trial, and the herbal granules may not prove more effective than placebo. Results may not apply to all Alzheimer's patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 570 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, age range : 50 - 80 years old. 2. Informed consent signed and dated by patient or legal representative. 3. The participants are mild-to-moderate AD patients who meet the diagnostic criteria for AD proposed by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in 2018 and have a disease course of more than 6 months. If participants lack previous pathological evidence or biomarkers of Alzheimer's dementia, they must have evidence of β-amyloid deposition biomarkers during screening (PET with abnormal amyloid deposition or low cerebrospinal fluid Aβ 42 and Aβ 42/Aβ 40 ratio). 4. MMSE score 11 to 26;CDR-GS score 1 to 2 。 Exclusion Criteria: 1. Participants with non AD induced memory and cognitive impairment, such as diagnosis of other types of dementia, including but not limited to mixed dementia (AD VaD), vascular dementia (VD), Parkinson's disease dementia (PDD), Lewy body dementia (DLB), Huntington's disease related dementia, frontotemporal lobe dementia (FTD), etc; Endocrine system disorders (such as thyroid diseases, parathyroid diseases) and dementia caused by folate, vitamin B12 deficiency, or any other reason; Existence of consciousness disorders, etc. 2. Participants have a history of epileptic seizures. 3. Participants are psychiatric patients, including but not limited to schizophrenia, affective schizophrenic disorder, bipolar disorder, or delirium. 4. HAMD-17 score ≥ 17 points. 5. HAMA score ≥ 14 points. 6. Participants were taking antidepressants, anxieties, and antipsychotic drugs during screening. 7. HIS score ≥ 4 points..
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer's dementia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fujian Medical University Affiliated Union Hospital
RECRUITINGFuzhou, Fujian, 350000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.